Ebola Virus - What should you know about the deadly virus?
We face many threats to our continuing survival as humans: from natural or manmade disasters to unseen pathogens only detectable at nm resolutions. This is not your fictional Zombie Apocalypse; the stakes are real and the deaths agonizing. In 2014, the world witnessed an explosion in cases and mortality from the deadly Ebola Virus, a known hemorrhagic virus endemic to Central Africa. Prior to 2014, only 1974 cases with 1250 known deaths had been recorded, mainly localized to a small equatorial belt of Central African countries (CDC statistics). Although greatly feared for the horrific symptomology, Ebola is not airborne and spreads only through direct contact with infected bodily fluids. This last, and most cautionary Ebola outbreak has exposed just how unprepared humanity is for rapid spread of viral diseases. In a snowball effect, one infected child began an epidemic resulting in close to 30,000 infections and 12,000 known fatalities. The ramifications and aftermath of Ebola infection and survival has become one of our most important Public Health research areas, as relapses from dormant virus are being identified, viral persistence in ocular and testicular tissues are being found by sensitive qPCR methologies and unknown carrier individuals risk reigniting local or worldwide disease.
Early clinical symptoms of Ebola can be difficult to distinguish from other common tropical fevers, making early diagnosis and effective interventions problematic for Public Health officials. Initial flu-like presentations are easily masked with OTC medications, leaving families of the victim and frontline healthcare providers unaware and unprotected. Once internal and external bleeding along with extensively vomiting with diarrhea begins, the mortality rate climbs steeply and the victim is highly contagious. 2015 has marked the beginning of our battle with Phase I safety trials for a potential vaccine completed and current recruitment for a staged Phase III trial in healthy volunteers for two candidate vaccine formulations. Effective vaccines, ramped up drug discovery efforts for treatment options and identification of native vectors for Ebola will hopefully contain future infections. But, many more unforeseen pathogens wait.
MyBioSource offers the following products for laboratory research on Ebola Virus:
- Ebola Virus (EBOV) Real Time RT-PCR Kit (Catalog #MBS598157)
- Human Ebola Virus IgG (EV-IgG) ELISA Kit (Catalog #MBS108923)
- Human Ebola Virus IgM (EV-IgM) ELISA Kit (Catalog #MBS108924)
- Human Ebola Virus ELISA Kit (Catalog #MBS047374)
- Anti-GP (Zarie Ebolavirus 2014) Rabbit Polyclonal Antiserum (Catalog #MBS432137)
- Recombinant Zaire ebolavirus Minor nucleoprotein VP30 (VP30) (Catalog #MBS1288327)